Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.
about
KASL clinical practice guidelines: management of chronic hepatitis BPotential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysisTenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.Unrecognized hepatitis B in pre-screened children with hematologic and oncologic conditions.Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective studyHBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients.Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.Treating chronic hepatitis B virus: Chinese physicians' awareness of the 2010 guidelinesOptions for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovirHepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.New therapeutic perspectives in HBV: when to stop NAs.A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System.High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years.Hepatitis B virus transmission in pre-adolescent schoolchildren in four multi-ethnic areas of England.
P2860
Q26752475-1D98D420-6007-4CE9-B614-E9258502B95AQ28074863-45AE5328-7360-4327-87A7-90D5075C1155Q30860824-3EBC048D-BE9D-45EC-BE02-9E8C2B7ACD68Q33411579-36B20B58-13FD-4146-8AAD-2C4A231F9C3DQ34289969-60F441E2-43DE-401C-9ECE-FE7FB3F2EA11Q34974141-70E962CB-3922-49EF-8960-D8F730D38989Q35706571-4A1D8804-D4B6-42CA-8CAB-12CBB6322495Q36014403-C2FE8AA1-C1EF-41E6-97A0-9F3642652891Q36153966-832EE1D0-4435-4203-A687-8659C55FB43DQ36756364-9CF3A06F-DFCA-411E-81FA-7799B2F8503CQ37039753-211116C9-9381-415D-A64B-F3D57B488285Q37229851-620BC6CF-1DBE-466D-9AA1-643D667758A3Q37334120-2E945E6A-6B7D-4E03-B472-F0FE2219DF6BQ37343296-A1446A38-C72E-4840-A0A9-A1B7801B37B4Q37588038-D48B7BBF-36C7-421A-8E8E-6C1CC108A900Q37724690-41E4CDCF-61D7-474C-8DC7-89E609124F00Q38174265-28361C08-884C-4E23-8E7A-40CD18AFC131Q40243616-1B3B93C7-623B-41A7-A6B6-94418CA56D5EQ42180497-CAD8F6FA-3C5F-4619-8777-6090AC784CC4Q42217489-DA1CAFE4-709A-42DE-9AE3-1AE70449B8F1Q44941493-1E37CADF-B76C-4FC6-8F56-B704F7202036
P2860
Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Chronic hepatitis B: whom to t ...... lenges, and future directions.
@ast
Chronic hepatitis B: whom to t ...... lenges, and future directions.
@en
type
label
Chronic hepatitis B: whom to t ...... lenges, and future directions.
@ast
Chronic hepatitis B: whom to t ...... lenges, and future directions.
@en
prefLabel
Chronic hepatitis B: whom to t ...... lenges, and future directions.
@ast
Chronic hepatitis B: whom to t ...... lenges, and future directions.
@en
P2093
P2860
P1476
Chronic hepatitis B: whom to t ...... llenges, and future directions
@en
P2093
APPROACH Working Group
Henry L Y Chan
Hyung Joon Yim
Jinlin Hou
Mahesh K Goenka
Man-Fung Yuen
Masao Omata
Seng Gee Lim
P2860
P2888
P304
P356
10.1007/S12072-010-9163-9
P577
2010-02-20T00:00:00Z
P5875
P6179
1034480703